JP2014511825A - サイトカイン活性の調節方法 - Google Patents

サイトカイン活性の調節方法 Download PDF

Info

Publication number
JP2014511825A
JP2014511825A JP2013548650A JP2013548650A JP2014511825A JP 2014511825 A JP2014511825 A JP 2014511825A JP 2013548650 A JP2013548650 A JP 2013548650A JP 2013548650 A JP2013548650 A JP 2013548650A JP 2014511825 A JP2014511825 A JP 2014511825A
Authority
JP
Japan
Prior art keywords
hydroxy
hydrogen
substituted
mono
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013548650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511825A5 (https=
Inventor
隆司 上野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of JP2014511825A publication Critical patent/JP2014511825A/ja
Publication of JP2014511825A5 publication Critical patent/JP2014511825A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013548650A 2011-04-19 2012-04-18 サイトカイン活性の調節方法 Ceased JP2014511825A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161476992P 2011-04-19 2011-04-19
US61/476,992 2011-04-19
US201161489516P 2011-05-24 2011-05-24
US61/489,516 2011-05-24
US201161537305P 2011-09-21 2011-09-21
US61/537,305 2011-09-21
US201161548458P 2011-10-18 2011-10-18
US61/548,458 2011-10-18
PCT/JP2012/061004 WO2012144649A1 (en) 2011-04-19 2012-04-18 Method for modulating cytokine activity

Publications (2)

Publication Number Publication Date
JP2014511825A true JP2014511825A (ja) 2014-05-19
JP2014511825A5 JP2014511825A5 (https=) 2015-06-11

Family

ID=47021806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013548650A Ceased JP2014511825A (ja) 2011-04-19 2012-04-18 サイトカイン活性の調節方法

Country Status (13)

Country Link
US (1) US20120270945A1 (https=)
EP (1) EP2699244A4 (https=)
JP (1) JP2014511825A (https=)
KR (1) KR20140043075A (https=)
CN (2) CN103781482A (https=)
AU (2) AU2012246999A1 (https=)
BR (1) BR112013026644A2 (https=)
CA (1) CA2831869A1 (https=)
IL (1) IL228700A0 (https=)
MX (1) MX2013012251A (https=)
RU (1) RU2013151166A (https=)
TW (1) TW201247615A (https=)
WO (1) WO2012144649A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2642744C (en) * 2006-02-28 2015-02-24 Sucampo Ag Method and composition for treating chronic obstructive pulmonary disease
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150099802A1 (en) * 2013-10-03 2015-04-09 Sucampo Ag Selective tumor treatment
US20160228403A1 (en) * 2013-10-04 2016-08-11 Tohoku University Agent for preventing or ameliorating renal dysfunction
US20160120840A1 (en) * 2014-10-30 2016-05-05 Sucampo Ag Method and composition for treating nonerosive reflux disease

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04330015A (ja) * 1990-04-27 1992-11-18 Ueno Seiyaku Oyo Kenkyusho:Kk 生化学的拮抗及び疾患処置剤
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
EP0690049A2 (en) * 1994-06-03 1996-01-03 R-Tech Ueno Ltd. Agent for treating hepato biliary diseases
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
JP2008528440A (ja) * 2005-01-27 2008-07-31 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
JP2008531468A (ja) * 2005-03-04 2008-08-14 スキャンポ・アーゲー 末梢血管疾患の処置のための方法および組成物
JP2008533195A (ja) * 2005-03-21 2008-08-21 スキャンポ・アーゲー 粘膜障害の処置のための方法および組成物
JP2008535774A (ja) * 2005-04-12 2008-09-04 スキャンポ・アーゲー 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
WO2008136519A1 (ja) * 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
JP2009528259A (ja) * 2006-02-28 2009-08-06 スキャンポ・アーゲー 慢性閉塞性肺疾患を処置するための方法および組成物
WO2009133863A1 (ja) * 2008-04-28 2009-11-05 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
BR112013009163A2 (pt) * 2010-10-15 2016-07-26 Scinopharm Kunshan Biochemical Technology Co Ltd processo para preparação de lubiprostona

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
JPH04330015A (ja) * 1990-04-27 1992-11-18 Ueno Seiyaku Oyo Kenkyusho:Kk 生化学的拮抗及び疾患処置剤
JPH0770054A (ja) * 1993-08-30 1995-03-14 R Tec Ueno:Kk 生化学的拮抗および疾患処置剤
EP0690049A2 (en) * 1994-06-03 1996-01-03 R-Tech Ueno Ltd. Agent for treating hepato biliary diseases
JPH1029942A (ja) * 1996-04-02 1998-02-03 Yoichi Ichikawa 慢性関節リウマチ治療剤
JP2008528440A (ja) * 2005-01-27 2008-07-31 スキャンポ・アーゲー 中枢神経系障害の処置のための方法および組成物
JP2008531468A (ja) * 2005-03-04 2008-08-14 スキャンポ・アーゲー 末梢血管疾患の処置のための方法および組成物
JP2008533195A (ja) * 2005-03-21 2008-08-21 スキャンポ・アーゲー 粘膜障害の処置のための方法および組成物
JP2008535774A (ja) * 2005-04-12 2008-09-04 スキャンポ・アーゲー 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
JP2009528259A (ja) * 2006-02-28 2009-08-06 スキャンポ・アーゲー 慢性閉塞性肺疾患を処置するための方法および組成物
WO2008136519A1 (ja) * 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Ｅｐ４アゴニストを含有してなる細胞傷害性ｔ細胞の活性化剤
WO2009133863A1 (ja) * 2008-04-28 2009-11-05 国立大学法人浜松医科大学 Ｅｐ１アゴニストを含有してなる免疫増強剤
JP2011032262A (ja) * 2009-06-30 2011-02-17 Sucampo Ag Ｎｓａｉｄの長期使用のための医薬組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GASTROENTEROLOGY, 2008, VOL.134(4), P.A-738(W1939), JPN6016002735, ISSN: 0003244144 *
J. PHARMACOL. SCI., 2011/2, VOL.115(SUPPLEMENT 1), P.266P, JPN6016002733, ISSN: 0003244142 *
岩手医学雑誌, 2000, VOL.52(4), P.297-304, JPN6016002731, ISSN: 0003244140 *
日本消化器病学会誌, 2004, VOL.101, P.A134, JPN6016002734, ISSN: 0003244143 *
現代医療, 1987, VOL.19(4), P.1348-1351, JPN6016002732, ISSN: 0003244141 *

Also Published As

Publication number Publication date
CN103781482A (zh) 2014-05-07
EP2699244A1 (en) 2014-02-26
CA2831869A1 (en) 2012-10-26
IL228700A0 (en) 2013-12-31
AU2017203276A1 (en) 2017-06-08
MX2013012251A (es) 2014-01-20
CN107028952A (zh) 2017-08-11
BR112013026644A2 (pt) 2016-12-27
KR20140043075A (ko) 2014-04-08
US20120270945A1 (en) 2012-10-25
TW201247615A (en) 2012-12-01
NZ616027A (en) 2015-09-25
RU2013151166A (ru) 2015-05-27
EP2699244A4 (en) 2014-10-22
AU2012246999A1 (en) 2013-10-17
WO2012144649A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
JP6084942B2 (ja) 水性組成物
AU2017203276A1 (en) Method for modulating cytokine activity
JP2011512323A (ja) 幹細胞の成長を調節するための方法および組成物
US5346921A (en) Treatment of inflammation with 15-keto-prostaglandin compounds
JP2004504350A (ja) 高眼圧症および緑内障処置用組成物
HK1252353A1 (zh) 治疗精神分裂症的方法
RU2577700C2 (ru) Фармацевтическая комбинация для лечения опухоли
TWI594751B (zh) 治療帶有腹瀉之腸躁症之方法
AU2010253720A1 (en) Pharmaceutical composition comprising prostaglandin derivatives for use in modulating claudin mediated functions and in the treatment of dermatological disorders
US20160120840A1 (en) Method and composition for treating nonerosive reflux disease
US20120277299A1 (en) Method for modulating ion transporter
JP2016521678A (ja) 幹細胞の腫瘍形成能の抑制方法
NZ616027B2 (en) Method for modulating cytokine activity
HK1196278A (en) Method for treating schizophrenia

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20141215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150417

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170306

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170328

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20170725